M1219
M1219 is a GSH/ATP dual near-infrared activated fluorescent probe that enables independent real-time monitoring of dynamic changes in intracellular GSH and ATP without spectral crosstalk (GSH: Ex=640 nm, Em=740~800 nm; ATP: Ex=594 nm/610 nm, Em=650~700 nm). M1219 not only visualizes the metabolic regulatory mechanism of TNBC under single/dual-target inhibition of SLC7A11/GLUT1 and accurately evaluates its in vivo efficacy, but also achieves precise localization of the TNBC tumor invasion boundary. M1219 can be used for the research of triple-negative breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C76H83ClN8O5S
- 分子量:1256.04
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
M1219 (0-24 h) is a bifunctional near-infrared fluorescent probe that can specifically, stably and independently detect GSH and ATP in cell-free buffer systems. Its detection range matches physiological concentrations, with an EC50 value of 6.711 mM for GSH and 4.108 mM for ATP[1].
M1219 (20 μM; 15 min) enables specific and independent detection of endogenous GSH and ATP in live 4T1 cells, thus allowing visualization of the dynamic changes of these molecules under the action of redox and energy metabolism regulators[1].
M1219 (15-60 min) enables high-contrast fluorescence imaging in breast cancer specimens for precise identification of tumor boundaries, thereby accurately distinguishing cancerous tissues from adjacent tissues[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
M1219 (Intratumoral injection) enables precise near-infrared fluorescence-guided resection of subcutaneous triple-negative breast cancer (TNBC) tumors in mice, achieving a negative surgical margin of <0.1 mm through high-contrast differentiation between tumor and normal tissues[1].
M1219 (1 mmol in 100 μL; intravenous injection; observation for 24 h after administration) exhibits low in vivo toxicity and favorable biosafety in healthy BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female)[1]
-
Dosage:0.5 mmol in 200 μL
-
Administration:tail vein injection; on days 0, 10, and 18 post-treatment initiation
-
Result:Showed similar dual-channel (GSH at 815 nm, ATP at 650 nm) fluorescence intensities in tumor regions across all treatment groups on day 0.
Reached GSH channel fluorescence intensity 0.091-fold of the PBS control group, and ATP channel fluorescence intensity 0.090-fold of the control group in tumors by day 18.
Confirmed ex vivo GSH and ATP channel fluorescence intensities of 0.1067-fold and 0.093-fold of the control group, respectively.
Demonstrated a significant negative correlation between fluorescence signal intensity and tumor growth inhibition and therapeutic efficacy.
化学情報
-
分子量 1256.04
-
分子式 C76H83ClN8O5S
-
SMILES
CCN(C1=CC2=C(C3(C4=C(C5=C(CC4)C=C(C=C5)N(C)C)O2)C6=C(C(N3CCN7CCN(C(CC[N+]8=C(C(C)(C9=C8C=CC=C9)C)/C=C/C%10=C(/C(CCC%10)=C/C=C%11N(C%12=C(C/%11(C)C)C=CC=C%12)C)SC%13=CC=C(C=C%13)[N+]([O-])=O)=O)CC7)=O)C=CC=C6)C=C1)CC.[Cl-]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)